The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS 2026 | Advances in the diagnosis, classification & prognostication of MDS
In this roundtable discussion, Valeria Santini, MD, University of Florence, Florence, Italy, Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Arjan van de Loosdrecht, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, Tariq Kewan, MD, Mayo Clinic, Rochester, MN, and Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, discuss advances in the diagnosis and prognostication of myelodysplastic syndromes (MDS). Dr Efficace highlights the importance of harmonizing how MDS clinical trials assess patient-reported outcomes, while Dr Della Porta discusses the potential of artificial intelligence to generate dynamic prognostic scores. Prof. van de Loosdrecht comments on standardizing flow cytometry and integrating it into MDS classification, and Dr Kewan addresses the unmet need in TP53-mutated MDS and the role of emerging technologies in identifying patient subsets. This roundtable discussion took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
